Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

RJ Tesi's Biography

RJ Tesi, CEO/CMO, Inmune Bio Inc

Dr. Tesi has been President, Chief Executive Officer and acting Chief Medical Officer of INmune Bio since the formation of the Company in September 2015. Dr. Tesi has been at the leadership level of biotech companies, both public and private since, 1997. His industry experience has focused on translating the biology of immunology, inflammation and immunosuppression as it applies to transplant, autoimmune disease, cancer and neurodegenerative disease into the clinic including designing and executing clinical develop programs and product commercialization strategies. Prior to joining industry, Dr. Tesi was a clinically active academic transplant surgeon with experience in liver, pancreas, intestinal and kidney transplantation. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician and Fellow of the American College of Surgery.

RJ Tesi Image

Neutralizing Soluble TNF to Overcome Resistance to Immunotherapy

Tuesday, 29 October 2019 at 14:15

Add to Calendar ▼2019-10-29 14:15:002019-10-29 15:15:00Europe/LondonNeutralizing Soluble TNF to Overcome Resistance to ImmunotherapyImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The

The complexity of TNF biology is not understood by scientists, biopharma or clinicians.  In cancer, soluble TNF promotes tumor growth, EMT and metastasis.  In the TME, sTNF directly or indirectly recruits MDSC, TAM and Tregs while decreasing the TIL infiltration.  The result is a tumor that grows, is resistant to therapy and prone to metastasis.  Neutralizing sTNF reverses these immunologic resistance factors to allow the patient’s immune system and immunotherapy to better control the tumor.  The therapy must be targeted, selective inhibitor of only sTNF.  Currently approved non-selective TNF inhibitors should not be used because they inhibit trans-membrane TNF to promote immunosuppression.  Pre-clinical and clinical data will be presented.

Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The